Healthy Participants
Conditions
Brief summary
Drug: 2 single oral doses of midazolam, 2 single oral doses of prednisolone , and clofutriben once daily for 16 days.
Detailed description
Approximately 16 healthy male and female participants will be enrolled at a single center in the US. Each participant will receive 2 single oral doses of midazolam , 2 single oral doses of prednisolone, and clofutriben once daily for 16 days. On each day that midazolam is administered, blood samples for midazolam analysis in plasma will be collected for 24 hours. On each day that prednisolone is administered, blood samples for prednisolone, prednisone, and 6β-hydroxyprednisolone analyses in plasma will be collected for 24 hours. Blood samples for clofutriben and metabolite (AS2570469) analyses in plasma will be collected for 24 hours after the first dose and during 2 intervals at steady state. Blood samples for cortisol and cortisone analyses will be collected for 24 hours after administration of prednisolone, clofutriben, and both trial interventions together, and prior to dosing of either trial intervention. Urine will be collected for analysis of clofutriben, prednisolone, and metabolites. Feces will be collected for analysis of clofutriben and metabolites. Safety and tolerability will be assessed.
Interventions
DRUGmidazolam
Drug: 2 single oral doses of midazolam ,
DRUGclofutriben once daily for 16 days
clofutriben once daily for 16 days
DRUG2 single oral doses of prednisolone
2 single oral doses of prednisolone
Sponsors
Sparrow Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female participants aged 18 to 75 years of age, * Body mass index of 18 to 35 kg/m2, * Taking no medications, * Are considered by the investigator to be in good general health.
Exclusion criteria
* In the opinion of the investigator, the participant is not suitable for entry into the trial or has any contraindication to midazolam or prednisolone.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax of midazolam. | 24 hours from dose | It will be concluded that there is no relevant interaction of clofutriben on midazolam if the 90% CIs for the Cmax ratios (midazolam + clofutriben)/midazolam alone) are contained within the \[80%, 125%\] interval. |
| AUC0-t of midazolam | 24 hours from dose | : It will be concluded that there is no relevant interaction of clofutriben on midazolam if the 90% CIs for the AUC0-t (midazolam + clofutriben)/midazolam alone) are contained within the \[80%, 125%\] interval. |
Countries
United States
Outcome results
None listed